1
|
Evans RJ, Pline K, Loynes CA, Needs S, Aldrovandi M, Tiefenbach J, Bielska E, Rubino RE, Nicol CJ, May RC, Krause HM, O'Donnell VB, Renshaw SA, Johnston SA. Correction: 15-keto-prostaglandin E2 activates host peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote Cryptococcus neoformans growth during infection. PLoS Pathog 2020; 16:e1009058. [PMID: 33147298 PMCID: PMC7641360 DOI: 10.1371/journal.ppat.1009058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
[This corrects the article DOI: 10.1371/journal.ppat.1007597.].
Collapse
|
2
|
Evans RJ, Pline K, Loynes CA, Needs S, Aldrovandi M, Tiefenbach J, Bielska E, Rubino RE, Nicol CJ, May RC, Krause HM, O’Donnell VB, Renshaw SA, Johnston SA. 15-keto-prostaglandin E2 activates host peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote Cryptococcus neoformans growth during infection. PLoS Pathog 2019; 15:e1007597. [PMID: 30921435 PMCID: PMC6438442 DOI: 10.1371/journal.ppat.1007597] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Accepted: 01/25/2019] [Indexed: 12/19/2022] Open
Abstract
Cryptococcus neoformans is one of the leading causes of invasive fungal infection in humans worldwide. C. neoformans uses macrophages as a proliferative niche to increase infective burden and avoid immune surveillance. However, the specific mechanisms by which C. neoformans manipulates host immunity to promote its growth during infection remain ill-defined. Here we demonstrate that eicosanoid lipid mediators manipulated and/or produced by C. neoformans play a key role in regulating pathogenesis. C. neoformans is known to secrete several eicosanoids that are highly similar to those found in vertebrate hosts. Using eicosanoid deficient cryptococcal mutants Δplb1 and Δlac1, we demonstrate that prostaglandin E2 is required by C. neoformans for proliferation within macrophages and in vivo during infection. Genetic and pharmacological disruption of host PGE2 synthesis is not required for promotion of cryptococcal growth by eicosanoid production. We find that PGE2 must be dehydrogenated into 15-keto-PGE2 to promote fungal growth, a finding that implicated the host nuclear receptor PPAR-γ. C. neoformans infection of macrophages activates host PPAR-γ and its inhibition is sufficient to abrogate the effect of 15-keto-PGE2 in promoting fungal growth during infection. Thus, we describe the first mechanism of reliance on pathogen-derived eicosanoids in fungal pathogenesis and the specific role of 15-keto-PGE2 and host PPAR-γ in cryptococcosis. Cryptococcus neoformans is an opportunistic fungal pathogen that is responsible for significant numbers of deaths in the immunocompromised population worldwide. Here we address whether eicosanoids produced by C. neoformans manipulate host innate immune cells during infection. Cryptococcus neoformans produces several eicosanoids that are notable for their similarity to vertebrate eicosanoids, it is therefore possible that fungal-derived eicosanoids may provoke physiological effects in the host. Using a combination of in vitro and in vivo infection models we identify a specific eicosanoid species—prostaglandin E2 –that is required by C. neoformans for growth during infection. We subsequently show that prostaglandin E2 must be converted to 15-keto-prostaglandin E2 within the host before it has these effects. Furthermore, we find that prostaglandin E2/15-keto-prostaglandin E2 mediated virulence is via activation of host PPAR-γ –an intracellular eicosanoid receptor known to interact with 15-keto-PGE2.
Collapse
Affiliation(s)
- Robert J. Evans
- Bateson Centre, Firth Court, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
| | - Katherine Pline
- Bateson Centre, Firth Court, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
| | - Catherine A. Loynes
- Bateson Centre, Firth Court, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
| | - Sarah Needs
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham, West Midlands, United Kingdom
| | - Maceler Aldrovandi
- Systems Immunity Research Institute, and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, South Glamorgan, United Kingdom
| | - Jens Tiefenbach
- Banting and Best Department of Medical Research, The Terrence Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada
- InDanio Bioscience Inc., Toronto, Ontario, Canada
| | - Ewa Bielska
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham, West Midlands, United Kingdom
| | - Rachel E. Rubino
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
| | - Christopher J. Nicol
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
| | - Robin C. May
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham, West Midlands, United Kingdom
| | - Henry M. Krause
- Banting and Best Department of Medical Research, The Terrence Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada
- InDanio Bioscience Inc., Toronto, Ontario, Canada
| | - Valerie B. O’Donnell
- Systems Immunity Research Institute, and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, South Glamorgan, United Kingdom
| | - Stephen A. Renshaw
- Bateson Centre, Firth Court, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
| | - Simon A. Johnston
- Bateson Centre, Firth Court, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
- Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, South Yorkshire, United Kingdom
- * E-mail:
| |
Collapse
|